Etiome's Temporal Biodynamics™ AI-powered platform is the first end-to-end solution to detect disease and preempt progression before it becomes too late Company emerges following four years of ...
March saw a handful of noteworthy hires in the agency, consultancy, and investor spaces, including some notable advisor hires ...
Flagship has initially committed $50 million to Etiome to advance the Temporal Biodynamics™ platform and develop an initial pipeline of preemptive medicines. Etiome was founded from Flagship ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results